Risperidone susceptibility factors

In a 9-week open study of risperidone for agitated behavior in 15 patients with dementia (modal dose 0.5 mg/day), extrapyramidal symptoms developed at some point during the trial in 8 patients, and cognitive skills were impaired in 3 patients (70). Similarly, in 22 patients with dementia and behavioral disturbances, treated with risperidone 1.5 mg/ day (range 0.5 mg qds to 3 mg bd), 50% had significant improvement, but 50% had some extrapyramidal symptoms (71). A further case of a severe extrapyramidal reaction in an old patient with dementia further illustrated these susceptibility factors (72). 

Attention deficit hyperactivity disorder (ADHD) may be a susceptibility factor for risperidone-induced tardive dyskinesia and withdrawal dyskinesia. Both conditions have occurred in patients with a past or recent history of attention deficit hyperactivity disorder. 

Susceptibility factors A study of tumour necrosis factor-alpha (TNF-a) in 99 patients with bipolar depression found that treatment with olanzapine, quetiapine, risperidone, paliperidone or clozapine was associated with significantly greater TNF-a and a higher likelihood of metabolic syndrome [74FI TNF-a was greater in those with metabolic syndrome and there was a significant effect on the indirect relationship between antipsychotic treatment and elevated waist circumference. 

Susceptibility factors A systematic review of the clinical effects of CYP2D6 polymorphisms on the pharmacogenetics of risperidone foxmci most studies reported nonsignificant trends but were limited by duration and power... 

---